Discounted Cash Flow
Organon & Co.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $7.8b | $3.2b | $-345.0m | 41.4% | $12.69 |
| 2020 | $6.5b (-16.0%) | $2.2b (-32.9%) | $-352.0m (-2.0%) | 33.1% (-20.1%) | $8.52 (-32.9%) |
| 2021 | $6.3b (-3.5%) | $1.4b (-37.5%) | $106.0m (130.1%) | 21.4% (-35.2%) | $5.33 (-37.4%) |
| 2022 | $6.2b (-2.1%) | $917.0m (-32.1%) | $-196.0m (-284.9%) | 14.9% (-30.7%) | $3.61 (-32.3%) |
| 2023 | $6.3b (1.4%) | $1.0b (11.6%) | $-251.0m (-28.1%) | 16.3% (10.0%) | $4.01 (11.1%) |
| 2024 | $6.4b (2.2%) | $864.0m (-15.5%) | $764.0m (404.4%) | 13.5% (-17.4%) | $3.36 (-16.2%) |
| 2025 | $6.2b (-2.9%) | $187.0m (-78.4%) | $538.0m (-29.6%) | 3.0% (-77.7%) | $0.72 (-78.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.